

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc Feldmann and Ravinder N. Maini
Serial No. : 09/921,937 Examiner: P. Gambel
Filed : August 3, 2001 Group Art Unit: 1644
For : ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE
TREATMENT OF AUTOIMMUNE DISEASE

1185 Avenue of the Americas
New York, New York 10036
October 27, 2003


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(e), being the only computer readable form submitted in connection with U.S. Serial No. 08/690,775, filed September 17, 1999, now U.S. Patent No. 6,270,766, issued August 7, 2001, and being requested by applicant to be used as the computer readable form for the instant application (09/921,937) under 37 C.F.R. §1.821(e), contains the same information as the written "Sequence Listing" (2 pages) that was submitted as part of the originally filed instant application (09/921,937).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Nicholas F. Muto, Ph.D.
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400